Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

ImmuCell Corporation (ICCC) vs Rallybio Corporation (RLYB)

ImmuCell Corporation and Rallybio Corporation are both Biotechnology companies. ImmuCell Corporation and Rallybio Corporation are of similar size ($90.6M and $88.2M). Rallybio Corporation trades at the lower P/E: 2.1× against 117×. ImmuCell Corporation grew revenue faster over the last twelve months: 8.49% against 1.18%. ImmuCell Corporation has the higher net margin (2.57% vs 0.00%) and the higher return on invested capital (7.84% vs −1,052.0%). Across the 19 metrics below, Rallybio Corporation leads on 12 and ImmuCell Corporation on 7.

Valuation

Metric ICCC RLYB Biotechnology median
P/E 117.38 2.06 7.88
P/S 2.93 110.39 11.47
P/B 2.87 1.00 2.52
Price to free cash flow 21.27 3.55 21.16
EV/EBITDA 14.22 n/m 0.74
EV/Sales 2.92 2.18 10.73
Earnings yield 0.85% 48.49% (28.84%)
Free cash flow yield 4.70% 28.17% (23.03%)

Profitability

Metric ICCC RLYB Biotechnology median
Gross margin 40.32% 100.00% 65.16%
Operating margin 12.60% 0.00% 0.00%
Net margin 2.57% 0.00% 0.00%
Free cash flow margin 13.79% 0.00% 0.00%
Return on equity 2.57% 64.86% (57.72%)
Return on assets 1.69% 61.12% (49.22%)
Return on invested capital 7.84% (1,052.03%) 0.00%

Growth

Metric ICCC RLYB Biotechnology median
Revenue growth (TTM) 8.49% 1.18% 5.64%
EPS growth (last fiscal year) 53.85% 85.06% —
Revenue growth, 5-year CAGR 12.50% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ICCC RLYB Biotechnology median
Debt to equity 0.26 0.00 0.00
Current ratio 4.75 27.26 4.73
Net debt to EBITDA 1.19 1.63 0.96

Dividend

Metric ICCC RLYB Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ICCC RLYB Biotechnology median
Market cap 90.55m 88.21m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack